24-Hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: Comparison with placebo and formoterol

Current Medical Research and Opinion

Volumn 25, Issue 10, 2009, Pages 2353-2359

  LaForce, Craig ^a   Korenblat, Phillip ^b   Osborne, Pamela ^c   Dong, Fang ^d   Higgins, Mark ^c  

^a North Carolina Clinical Research   (United States)

^b Clinical Research Center   (United States)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Asthma; Bronchodilation; FEV1; Formoterol; Indacaterol; Single dose

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; GLUCOSE; INDACATEROL; PLACEBO; POTASSIUM; SALBUTAMOL; THEOPHYLLINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; MORNING DOSAGE; NOSE CONGESTION; POTASSIUM BLOOD LEVEL; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; PLACEBOS; QUINOLONES; YOUNG ADULT;

EID: 70349337022     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903143143     Document Type: Article

References (17)

1. Masoli M, Fabian D, Holt S, et al. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-478
2. Masoli M, Fabian D, Holt S, et al. Global burden of asthma. Report developed for the Global Initiative for Asthma, 2004. [Available at http://www.ginasthma.org. Accessed: 16 October 2007]
3. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH publication 02-3659 issued January 1995 (updated November 2007. [Available at: www.ginasthma.com. Accessed on: 1 December 2007]
4. Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10:2441-2442 (Pubitemid 28048620)
5. van Noord JA, Smeets JJ, Raaijmakers JA, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996;9:1684-1688
6. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? Ann Allergy Asthma Immunol 1997;79:177-185
7. van Schayck CP, Bijl-Hofland ID, Folgering H, et al. Influence of two different inhalation devices on therapy compliance in asthmatic patients. Scand J Prim Health Care 2002;20:126-128 (Pubitemid 34764232)
8. Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 2007;81:108-113 (Pubitemid 46050875)
9. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. E14 Clinical evaluation of QT/QTc interval prolongation and proarhythmic potential for non-antiarrhythmic drugs. October 2005. Available at: http://www.fda.gov/cder/guidance/index.htm
10. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-968 (Pubitemid 41632054)
11. 2-agonist, in patients with asthma: a dose-ranging study. J Asthma 2008;45:887-892
12. Beeh KM, Derom E, Kanniess F, et al. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007;29:871-878 (Pubitemid 46711890)
13. LaForce C, Alexander M, Deckelmann R, et al. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy 2008;63:103-111 (Pubitemid 350198242)
14. 2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol 2008;101:90-95
15. Pascoe S, Reynolds C, Pleskow W, et al. Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma. Eur Respir J 2007;30(Suppl 51):350s (P2115)
16. Chuchalin AG, Tsoi AN, Richter K, et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 2007;101:2065-2075 (Pubitemid 47336870)
17. Yang WH, Martinot JB, Pohunek P, et al. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann Allergy Asthma Immunol 2007;99:555-561 (Pubitemid 350308756)